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Abstract
Aims To study the impact of glycaemic control on urinary incontinence in women who participated in the Diabetes
Control and Complications Trial (DCCT; 1983–1993) and its observational follow-up study, the Epidemiology of
Diabetes Interventions and Complications (EDIC; 1994–present).
Methods Study participants were women who completed, at both years 10 (2003) and 17 (2010) of the EDIC follow-
up, the urological assessment questionnaire (UroEDIC). Urinary incontinence was defined as self-reported involuntary
leakage of urine that occurred at least weekly. Incident urinary incontinence was defined as weekly urinary incontinence
present at EDIC year 17 but not at EDIC year 10. Multivariable regression models were used to examine the association
of incident urinary incontinence with comorbid prevalent conditions and glycaemic control (mean HbA1c over the first
10 years of EDIC).
Results A total of 64 (15.3%) women with Type 1 diabetes (mean age 43.6  6.3 years at EDIC year 10) reported
incident urinary incontinence at EDIC year 17. When adjusted for clinical covariates (including age, DCCT cohort
assignment, DCCT treatment arm, BMI, insulin dosage, parity, hysterectomy, autonomic neuropathy and urinary tract
infection in the last year), the mean EDIC HbA1c was associated with increased odds of incident urinary incontinence
(odds ratio 1.03, 95% CI 1.01–1.06 per mmol/mol increase; odds ratio 1.41, 95% CI 1.07–1.89 per % HbA1c increase).
Conclusions Incident urinary incontinence was associated with higher HbA1c levels in women with Type 1 diabetes,
independent of other recognized risk factors. These results suggest the potential for women to modify their risk of
urinary incontinence with improved glycaemic control. (Clinical Trials Registry no: NCT00360815 and NCT00360893).
Diabet. Med. 33, 1528–1535 (2016)
Introduction
Urinary incontinence (UI), or the complaint of involuntary
leakage of urine, is one of the most prevalent chronic
conditions in women. Although the estimated prevalence of
UI varies depending on the definition applied and the age
range of the population under study, on average 20–25% of
women aged 40–50 years report having UI, leading to
significant distress and reduced quality of life [1]. Epidemi-
ological studies suggest that diabetes is an independent risk
factor for UI in women [2,3]. The evidence regarding the
effect of poor glycaemic control on subsequent UI among
women with diabetes, however, is limited and unclear. It has
been hypothesized that poor glycaemic control couldCorrespondence to: Aruna V. Sarma. e-mail: asarma@umich.edu
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contribute to this problem, either acutely by causing glyco-
suria, or chronically, by causing neuropathy [4,5]; however,
recent studies have failed to show an association between
glycaemic control and UI in women with diabetes [6–9]. The
studies were limited by their cross-sectional design, inclusion
of women primarily with Type 2 diabetes and relatively small
sample of women with poor glycaemic control.
The objective of the present study was to determine
whether long-term mean HbA1c levels among women with
Type 1 diabetes were associated with UI development after
accounting for established risk factors. We hypothesized that
poor glycaemic control in Type 1 diabetes may result in an
increased risk of UI. We examined the relationship between
HbA1c levels and UI using data from the Diabetes Control
and Complications Trial (DCCT) and its observational
follow-up, the Epidemiology of Diabetes Interventions and
Complications (EDIC) study. The DCCT/EDIC study has
collected detailed information on subjects with Type 1
diabetes since 1983. Information regarding UI has been
collected since 2003 in an ancillary study of urological
complications of diabetes (UroEDIC).
Patients and methods
Population and setting
The DCCT was a multicentre, randomized clinical trial
designed to compare the effects of intensive and conventional
diabetes therapy on the development and progression of early
microvascular and neuropathic complications of Type 1
diabetes [10]. From 1983 to 1989, 1441 patients (including
680 women) aged 13–39 years were recruited at 29 centres.
The DCCT included a primary prevention cohort and a
secondary intervention cohort. The primary prevention
cohort included 348 women with a diabetes duration of 1–
5 years at baseline, no retinopathy and a urinary albumin
excretion rate < 40 mg/24 h. The secondary intervention
cohort included 332 women with diabetes duration of 1–
15 years at baseline, non-proliferative retinopathy and a
urinary albumin excretion rate ≤ 200 mg/24 h. Individuals
were excluded if they had hypertension, a history of symp-
tomatic ischaemic heart disease, or the presence of symp-
tomatic peripheral neuropathy requiring therapy. The
intensive-therapy regimen was designed to achieve glycaemic
control as close to the non-diabetes range as safely possible
with ≥ 3 daily insulin injections or by use of an insulin pump,
with insulin dose adjustment guided by frequent self-monitor-
ing of blood glucose. Conventional therapy consisted of 1–2
daily insulin injections without prespecified target glucose
levels and aimed for absence of symptomatic hyperglycaemia
or frequent or severe hypoglycaemia. At the end of the trial in
1993, after a mean follow-up of 6.5 years, the DCCT proved
that intensive therapy significantly reduced the risks of
microvascular complications compared with conventional
treatment [11]. Intensive treatment was subsequently encour-
aged for all subjects,who then returned to their ownhealthcare
providers for ongoing diabetes care.
In 1994, 655 (96%) of the 680 surviving women (mean
age 35  7 years), volunteered to participate in the EDIC
study. During EDIC year 10 (2003–2004), 550 of the 652
active female participants (84%), agreed to participate in the
UroEDIC study, an ancillary study to examine the presence
of urological complications, including UI, lower urinary tract
symptoms, urinary tract infections and sexual dysfunction. In
EDIC year 17 (2010–2011), 580 of the 618 active female
participants (94%), completed the UroEDIC protocol. A
total of 500 women (mean age 51  7 years), provided
information on UI at both EDIC years 10 and 17. Of these
500 women, 417 did not report UI at EDIC year 10 and were
eligible for the study of incident UI at EDIC year 17 (Fig. 1).
The institutional review board of each participating centre
approved the study.
Measurement of urinary incontinence
Assessment of UIwas performed at EDIC years 10 and 17with
a self-administered questionnaire using validated instruments
from previous studies [12]. The sequence of incontinence
questions began with, ‘During the past 12 months how often
have you leaked even a small amount of urine. . .’. The
frequency of incontinence was ascertained as every day, ≥ 1
time weekly, ≥ 1 time monthly, or < 1 time per month. The
primary outcome of interest was weekly or more frequent UI,
which we defined as ‘weekly UI’. Those subjects with less than
weekly or noUIwere defined as having ‘noUI’. Amongwomen
withweeklyUI, the type of incontinence during the past 7 days
was classified by answers to the additional questions, ‘. . .dur-
ing activities such as coughing, sneezing, lifting or exercise?”
(stress incontinence) and ‘. . .with an urge to urinate and could
not get to the bathroom fast enough?’ (urge incontinence).
Those who reported both types were placed in the category
‘mixed incontinence’. Incident UI was defined by cases of
weekly UI present at EDIC year 17 but not at EDIC year 10.
Urinary tract infection was also assessed at EDIC years 10 and
What’s new?
 Research to date has failed to show an association
between glycaemic control and urinary incontinence
(UI) in women with diabetes.
 We examined the relationship between HbA1c and UI
using longitudinal data from the Diabetes Control and
Complications Trial (DCCT) and its observational
follow-up, the Epidemiology of Diabetes Interventions
and Complications (EDIC) study.
 Our findings show that the odds of UI increase with
poor glycaemic control in women with Type 1 diabetes,
independently of other well-described predictors of UI.
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17 by self-report with the following question, ‘How many
times were you diagnosed by a physician with a bladder
infection in the previous 12 months?’. For the purposes of the
present study, urinary tract infection at EDIC year 10 was
defined as ≥ 1 episode in the past 12 months.
Diabetes measurements
Each partipant in the EDIC study underwent an annual
medical history, physical examination and laboratory testing
including HbA1c, using the same methods as those used
during the DCCT [13]. HbA1c levels were measured at
baseline and quarterly during the DCCT, and annually in the
EDIC study using high-performance ion-exchange liquid
chromatography, as previously described [14]. For the
purposes of the present analysis, we used the mean HbA1c
during EDIC years 1–10 as the exposure variable. This time
frame was chosen to ensure temporality of the HbA1c and UI
relationship, as annual UI development was not available
between the years 10 and 17. Retinopathy was assessed using
fundus photographs that were centrally graded using the
Early Treatment Diabetic Retinopathy Study scale. The
albumin excretion rate was measured in half of the cohort
annually. Nephropathy was defined as an albumin excretion
rate > 30 mg/24 h. Peripheral neuropathy was defined by the
Michigan Neuropathy Screening Instrument as > 6 responses
on the questionnaire or a score of > 2 on the examination.
Abnormal cardiovascular autonomic neuropathy was defined
as: either R-R variation < 15 or R-R variation between 15
and 19.9, plus either a Valsalva ratio ≤ 1.5 or a supine-to-
standing drop of ≥ 10 mm Hg in diastolic blood pressure.
Statistical analysis
The distribution of demographic and clinical characteristics,
cohort and treatment, markers of diabetes control and
FIGURE 1 Flow of participants in the DCCT/EDIC/UroEDIC study. DCCT, Diabetes Control and Complications Trial; EDIC, Epidemiology of
Diabetes Interventions and Complications study; UroEDIC, EDIC substudy on urological complications; UI, urinary incontinence.
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microvascular complications at EDIC year 10 were com-
pared according to incident weekly UI status at EDIC year 17
using the chi-squared test for categorical variables and the
Wilcoxon rank-sum test for continuous variables. A multi-
variable logistic regression model was used to estimate the
association between glycaemic control (mean HbA1c from
EDIC year 1 to year 10) and incident weekly UI at EDIC year
17. Adjustments for a priori predictors of UI described in the
literature and those that were significant in bivariate analyses
were performed. The following EDIC year 10 adjustment
variables were used for multivariable models: age; DCCT
cohort assignment; DCCT treatment arm; EDIC mean BMI;
total daily insulin dosage; parity; hysterectomy; autonomic
neuropathy; and urinary tract infection in the last year.
Table 1 Participant characteristics at EDIC year 10 by incident weekly urinary incontinence status at EDIC year 17




(n = 64) P*
Sociodemographic and clinical characteristics
Mean (SD) attained age (years) 43.1  7.4 43.6  6.3 0.69
Smoker†, n (%) 49 (14) 8 (13) 0.77
Drinker†, n (%) 125 (35) 23 (36) 0.94
Race, n (%)
Non-Hispanic white 343 (97) 63 (98) 0.53
Non-Hispanic black 7 (2) 0 (0)
Other 3 (1) 1 (2)
Parity (n of live births), n (%)
0 106 (30) 16 (25) 0.53
1 64 (18) 15 (23)
≥ 2 183 (52) 33 (52)
Hysterectomy‡, n (%) 35 (10) 3 (7) 0.17
Postmenopausal, n (%) 86 (25) 12 (19) 0.28
Mean (SD) BMI, kg/m2
EDIC mean up to year 10 26.3  4.1 27.4  4.5 0.08
EDIC year 10 27.0  4.8 27.8  5.1 0.27
Mean (SD) BMI gain during EDIC, kg/m2 1.4  3.1 1.4  3.1 0.48
Urinary tract infection (within past year)§, n (%) 52 (15) 12 (19) 0.44
Diabetes control and treatment
DCCT cohort, n (% primary prevention) 183 (52) 32 (50) 0.79
Treatment group, n (% intensive) 178 (50) 42 (66) 0.03
Mean (SD) HbA1c, mmol/mol
EDIC year 1 62  14 68  16 0.01
EDIC year 10 61  14 68  15 0.001
EDIC mean up to year 10 63  12 68  14 0.003
Mean (SD) HbA1c, %
EDIC year 1 7.8  1.3 8.3  1.5 0.01
EDIC year 10 7.8  1.2 8.4  1.4 0.001
EDIC mean up to year 10 7.9  1.1 8.4  1.2 0.003
Mean (SD) insulin dose, units/kg/day
EDIC year 10 0.60  0.23 0.69  0.25 0.003
EDIC mean up to year 10 0.55  0.17 0.59  0.16 0.03
Microvascular complications
Retinopathy¶, n (%) 50 (15) 10 (16) 0.82
Nephropathy¶ , n (%) 43 (13) 5 (8) 0.30
Peripheral neuropathy**, n (%) 102 (29) 22 (34) 0.38
Autonomic neuropathy††, n (%) 98 (30) 23 (37) 0.25
DCCT, Diabetes Control and Complications Trial; EDIC, Epidemiology of Diabetes Interventions and Complications study.
*P values based on the Wilcoxon rank-sum test for quantitative characteristics or the contingency chi-squared test for qualitative
characteristics.
†Smoking was defined as ‘currently smokes cigarettes or ever smoked in the past 12 months (any amount)’. Drinking was defined as
‘consumed an average of at least one alcoholic beverage per week during the past 12 months’
‡Hysterectomy defined by report of surgically induced menopause.
§Urinary tract infection was determined at EDIC year 10 by self-report with the following question, ‘How many times were you diagnosed by
a physician with a ‘bladder infection’ in the previous 12 months?’. Urinary tract infection was defined as ≥ 1 episode in past 12 months.
¶Defined up to EDIC year 10 using the Early Treatment Diabetic Retinopathy Study on a scale of 0–23. Proliferative diabetic retinopathy is
defined as ≥ 12 and/or scatter or focal laser.
¶Defined at EDIC year 9/10 as albumin excretion rate (mg/24 h) > 30.
**Defined at EDIC year 10 by the Michigan Neuropathy Screening Instrument > 6 responses on the questionnaire or a score of > 2 on the
examination.
††Defined at EDIC year 13/14 as R-R variation < 15 or RR variation < 20 in combination with a Valsalva ratio ≤ 1.5 or a decrease of
> 10 mm Hg in diastolic blood pressure upon standing.
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Effects nominally significant at P ≤ 0.05 are reported. All
analyses were performed using SAS version 9.3 (SAS Institute,
Cary, NC, USA).
Results
Among the 417 women who did not report at least weekly UI
at EDIC year 10, 64 reported at least weekly UI at EDIC year
17 representing an incidence of weekly UI of 15.3% over this
7-year time frame. These women were classified as having
either mixed UI (n = 29, 45.3%), stress UI (n = 27, 42.2%)
or urge UI (n = 5, 7.8%). Type of UI was not specified by
three (4.7%) women. There were no significant differences in
the characteristics of women with and without UI at EDIC
year 10 with respect to age, race, parity, menopausal status,
hysterectomy or urinary tract infection within the past year
(Table 1). Mean BMI up to EDIC year 10 was greater in
women reporting incident UI compared with women report-
ing less frequent UI (P = 0.08). Intensive vs conventional
therapy assignment during DCCT was associated with
incident weekly UI during the EDIC study (P = 0.03), with
a higher frequency of incident UI in women assigned to
intensive therapy during the DCCT. The DCCT cohort
(primary vs secondary) was not associated with incident
weekly UI (P = 0.79).
Women with incident weekly UI had higher mean HbA1c
levels at EDIC year 1 [68  16 mmol/mol (8.3  1.5%) vs
62  14 mmol/mol (7.8  1.3%); P = 0.01] and EDIC year
10 [68  15 mmol/mol (8.4  1.4%) vs 61  14 mmol/
mol (7.8  1.2%); P = 0.001] as compared with women
who did not develop UI by EDIC year 17. Similarly, mean
HbA1c up to EDIC year 10 was higher in women with
incident weekly UI compared with women who did not
develop UI between EDIC years 10 and 17 [68  14 mmol/
ml (8.4  1.2%) vs 63  12 mmol/mol (7.9  1.1%);
P = 0.003]. Women with weekly UI also reported a higher
mean daily dose of insulin during EDIC years 1–10
(0.59  0.16 vs 0.55  0.17 units/kg/day; P = 0.03). The
frequency of diabetes-associated microvascular complica-
tions, such as proliferative retinopathy, nephropathy, periph-
eral neuropathy and autonomic neuropathy, did not differ
between women with and without incident weekly UI
(Table 1).
A multivariable logistic regression model was used to
estimate the association between unit changes in glycaemic
control and incident weekly UI after adjustment for age,
DCCT treatment group, DCCT cohort assignment, BMI,
EDIC mean daily insulin dose, parity, hysterectomy, auto-
nomic neuropathy and UTI (Table 2). Long-term poor
glycaemic control, as defined by higher mean HbA1c levels
in EDIC years 1–10 was associated with an increased risk of
UI (odds ratio 1.03, 95% CI 1.01–1.06 per mmol/mol
increase in HbA1c; odds ratio 1.41, 95% CI 1.07–1.89 per %
increase in HbA1c). Age, DCCT cohort assignment, DCCT
treatment arm, BMI, EDIC mean insulin dosage, parity,
hysterectomy, autonomic neuropathy and UTI in the last
year were not significantly associated with incident UI
independently of HbA1c. Additional analysis examining
tertile distribution of HbA1c showed an increasing risk of
UI with increasing HbA1c levels. Women with EDIC mean
HbA1c levels in the second tertile [58–67 mmol/mol (7.38–
8.23%)] had a 1.44 greater odds of UI, while those with
levels in the highest tertile [≥ 67 mmol/mol (8.23%)] had a
2.50 greater odds of developing UI compared with women
with HbA1c levels < 58 mmol/mol (7.38%; Fig. 2).
Discussion
The present study is the first to show the impact of glycaemic
control on risk of UI among women with Type 1 diabetes.
After adjustment for previously well-described risk factors,
we observed a 3 and 41% increased odds of incident weekly
Table 2 Adjusted multivariable logistic regression model examining the effect of glycaemic exposure on incident weekly urinary incontinence status
at EDIC year 17
Risk factors at EDIC year 10 Odds ratio (95% CI) P
Attained age (per year) 1.02 (0.97, 1.06) 0.53
DCCT cohort (primary prevention vs secondary intervention) 0.90 (0.50, 1.64) 0.74
DCCT treatment group (intensive vs conventional) 1.71 (0.92, 3.19) 0.09
EDIC mean BMI up to year 10 (kg/m2) 1.05 (0.97, 1.12) 0.21
EDIC mean insulin dose up to year 10 (units/kg/day) 3.01 (0.50, 18.22) 0.23
Parity (n of live births)
1 vs 0 1.79 (0.75, 4.27) 0.23
≥ 2 vs 0 1.33 (0.63, 2.83) 0.99
Hysterectomy (yes vs no) 0.31 (0.08, 1.21) 0.09
Autonomic neuropathy (yes vs no) 1.03 (0.51, 2.08) 0.93
Urinary tract infection (within past year) (yes vs no) 1.34 (0.62, 2.91) 0.46
EDIC mean HbA1c up to year 10 (mmol/mol) 1.03 (1.01, 1.06) 0.02
EDIC mean HbA1c up to year 10 (%) 1.41 (1.07, 1.89) 0.02
DCCT, Diabetes Control and Complications Trial; EDIC, Epidemiology of Diabetes Interventions and Complications study.
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UI associated with each 1-mmol/mol and 1% increase in
HbA1c level, respectively, in women with Type 1 diabetes.
This association was independent of age, DCCT cohort
assignment, DCCT treatment arm, BMI, insulin dosage,
parity, hysterectomy, abnormal cardiovascular autonomic
neuropathy and UTI in the last year. These data suggest that
long-term glycaemic control may independently affect the
development of UI in this population.
In contrast to the findings of the present study, previous
studies have failed to identify an association between level of
glycaemic control and UI [6–9]. In a study of women aged
55–75 years, enrolled in a group health plan, Jackson et al.
[15] found no associations between HbA1c (categorized as
≤ 7.5%, 7.6–8.5% and > 8.5%) and UI. Similarly, Phelan
et al. [7] did not observe a relationship between HbA1c and
UI among 2994 overweight/obese women with diabetes.
Previous work in this cohort at EDIC year 10 also did not
find an association between HbA1c levels and prevalent UI
[16,17]. There are several possible explanations for the
discrepant findings between previous studies and the present
results. First, the earlier studies included women almost
exclusively with Type 2 diabetes and were limited in their
cross-sectional designs. Second, these studies used measure-
ment of HbA1c at a single time point, a measure of current
control (average glycaemic control over a period of a several
months), while we used a measure of average glycaemic
control over years of diabetes. Third, the average BMI in
several of these studies was > 35 kg/m2 and it is possible that
the greater weight may have impaired the detection of the
effects of these measures on UI. Interestingly in a recent
report of the Diabetes and Aging Study, a sample of women
with Type 1 and 2 diabetes enrolled in the Kaiser Permanente
Northern California Diabetes Registry, HbA1c level was not
associated with presence or absence of UI, but poor
glycaemic control, defined as HbA1c ≥ 9%, was associated
with more limitations in daily activities as a result of UI [6].
This is consistent with the present findings that the largest
impact of glycaemic control on incident UI was among those
with the highest tertile of HbA1c levels [≥ 67 mmol/mol
(8.23%)].
The present findings showing that poor glycaemic control is
associated with UI in patients with long duration of Type 1
diabetes is consistent with effects found with other diabetes
complications.Microvascular and neurological complications
of Type 1 diabetes, which are established pathological
consequences of poor glycaemic control [11,18,19], result in
changes that might damage innervation of the bladder or alter
bladder muscle function, which may precipitate or worsen
urinary symptoms [4,5,20,21]. Hyperglycaemia also causes
increased glucosuria and urine volume, which could be a
contributing factor. Improving glycaemic control has been
advocated as a means of improving urinary symptoms [22].
Interestingly, we observed that those women initially
randomized during the DCCT to the intensive treatment
arm (as opposed to conventional treatment) have a higher
incidence of weekly UI in bivariate analyses. It is possible
that this is related to increased insulin exposure in the
intensive treatment group, resulting in insulin-related weight
gain [23,24] which could cause increased intra-abdominal
pressure and lead to increased bladder pressure and urethral
mobility [25,26]. Notably, after multivariable model adjust-
ment for mean insulin dose and BMI during the EDIC
interval, the effect of randomization to intensive treatment
on UI risk was no longer statistically significant. Further
studies examining the complex relationship between insulin
dose and effects on body size are necessary.
There are several important clinical implications for the
present findings. First, the 7-year incidence (15.3%) of
weekly UI in the present study is lower than that observed for
other populations [27,28]. While this could be a function of
the variation in the definition of UI across studies, it is also
possible that this is a result of improved glycaemic control,
which may have contributed to the prevention of symptoms.
We cannot exclude the additional possibility that women
with Type 1 diabetes may be less likely to report or discuss
urinary symptoms [29]. Second, for women with Type 1
diabetes our data suggest that improved glycaemic control
may decrease the risk of incident UI. These findings provide a
compelling argument for the routine assessment and coun-
selling for UI in women with Type 1 diabetes. Offering
women the knowledge that they can potentially decrease
their risk of UI with improved glycaemic control might
motivate some women to improve their self-care. This may
















Tertiles of mean HbA1c mmol/mol (%) up to EDIC Year 10 
P=0.0583 
FIGURE 2 Multivariable adjusted odds ratios of incident weekly
urinary incontinence (UI) at Epidemiology of Diabetes Interventions
and Complications study (EDIC) year 17 by tertiles of HbA1c (EDIC
mean HbA1c up to year 10 [HbA1c reference < 58 mmol/mol or
< 7.38%)]. P value based on overall Wald chi-squared test for
parameter estimate of HbA1c in the multivariable logistic regression
model. Odds of incident weekly UI at EDIC year 17 adjusted for the
following EDIC year 10 characteristics: attained age; Diabetes Control
and Complications Trial (DCCT) cohort assignment; DCCT treatment
group; EDIC mean daily insulin dose; EDIC mean BMI; parity;
hysterectomy; autonomic neuropathy; and urinary tract infection.
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have been found to be less effective in women with diabetes
[30].
The present study is the largest examination of the impact
of glycaemic control on UI in the literature among women
with Type 1 diabetes. Its strengths include the minimal loss
to follow-up and frequent validated measurement of key
covariates. The long duration of follow-up allowed the
exploration of long-term glycaemic control and BMI, and
their relative impact on UI risk. The study also has several
limitations. While the cohort has been followed for many
years, participants are still relatively young and almost all are
white. Also, DCCT/EDIC participants are generally a highly
motivated group of individuals who have been followed for
many years with a goal of good diabetes control, so these
results may not apply to a broader population with Type 1
diabetes. Further, it is unclear whether these results extend to
women with Type 2 diabetes, who generally have a different
demographic profile from women with Type 1 diabetes, and
have a later age of diabetes onset and a higher prevalence of
obesity. Finally, we were unable to evaluate the impact of
glycaemic control on specific types of UI because of the
limited sample size and power. Further longitudinal follow-
up of this cohort should enable these events to be examined.
In conclusion, the present findings show that the odds of
UI increase with poor glycaemic control in women with Type
1 diabetes. This relationship is independent of other well-
described predictors of UI and suggests that factors directly
related to glycaemic control may be affecting urinary
symptoms. Offering women the knowledge that they can
potentially decrease their risk of UI with aggressive glycaemic
control might motivate women to more strictly adhere to
glycaemic therapies to reduce other more serious risks of
diabetes sequelae.
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